Brief: Monte Rosa Therapeutics Q4 EPS USD -0.58
14/03/2024 11:00
Mar 14 (Reuters) - Monte Rosa Therapeutics Q4 operating expenses USD 34.863 million. * Q4 operating income USD -34.863 million * Q4 net income USD -33.252 million * Q4 pretax profit USD -33.274 million
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million